66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Poster

Halls G-H (San Diego Convention Center)

Preclinical Study of HLA Class I-Edited Allogeneic iPSC-Derived Virus-Specific T Cells Targeting Epstein-Barr Virus-Associated Lymphomas

Kosuke Matsuzaki¹^*, Midori Ishii¹^*, Shintaro Kinoshita¹^*, Ayaka Goto¹^*, Yoko Azusawa²^*, Yoshiki Furukawa¹^*, Jun Ando^1,2^*, Hiromitsu Nakauchi^3,4^* and Miki Ando¹

¹Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
²Division of Cell Therapy & Blood Transfusion Medicine, Juntendo University School of Medicine, Tokyo, Japan
³Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford
⁴Stem Cell Therapy Laboratory, Advanced Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

4812

CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

Maday Galeana Figueroa, MSc¹^*, Kishan Nyati, PhD¹^*, Tarang Sharma²^*, Binod Dhakal, MBBS¹, Meera Mohan, MD¹, Parameswaran N. Hari, MD, MBBS¹ and Sabarinath Venniyil Radhakrishnan, MD, MBBS¹

¹Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
²Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Wauwatosa, WI

4813

A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Idan Milo¹^*, Nofar Azulay¹^*, Yuval Bussi¹^*, Raz Ben Uri¹^*, Tal Keidar-Haran²^*, Michal Eldar¹^*, Ofer Elhanani¹^*, Yotam Harnik¹^*, Oran Yakubovsky^1,3,4^*, Ido Nachmany³^*, Tomer Salame⁵^*, Philippe Bertheau⁶^*, David Michonneau, MD, PhD⁷^*, Gerard Socie^8,9 and Leeat Keren¹^*

¹Department of Molecular Cell Biology, Weizmann Institute of science, Rehovot, Israel
²Department of Pathology, Hadassah Medical Center, Rehovot, Israel
³Department of General Surgery and Transplantation, Sheba Medical Center, Ramat Gan, Israel
⁴Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁵Weizmann Institute of Science, Rehovot, ISR
⁶Hosp Saint-Louis, Paris, FRA
⁷Hematology and transplantation, Saint-Louis Hospital, APHP, Paris, France
⁸Hematology Transplantation, Paris, France
⁹INSERM UMR 976, Institut de Recherche Saint-Louis, Paris, France

4814

Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Salomé Decombis^1,2,3^*, Johannes Smolander, PhD^1,2,3^*, Jonas Bouhlal, MSc, BSc^1,2,3^*, Jay Klievink, M.Sc^1,2,3^*, Hanna Lähteenmäki, MSc^1,2,3^*, Emmi Jokinen^1,2,3^*, Linh Lin^2,3^*, Hanna Laitinen^2,3^*, Konstantin Matjusinski^1,2,3^*, Eveliina Holappa^1,2,3^*, Mikko Myllymäki, MD, PhD^1,2,3, Heidi Haikala, PhD^2,3^*, Sara Gandolfi, MD, PhD^1,2,3^* and Satu Mustjoki, MD, PhD^1,2,3

¹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
²Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
³ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland

4815

Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Daniel J. Chandra, MD^1,2, Faith Burns¹^*, Austin Nguyen, PhD³^*, Elias Pavlatos, PhD³^*, Khauan Bainha³^*, Nicola Long¹^*, Yoko Kosaka, PhD¹^*, Jessica Mulkey¹^*, Joanna Pucilowska, PhD³^*, Evan F. Lind, PhD¹, Jeffrey W. Tyner, PhD¹ and Jennifer N. Saultz, DO¹

¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR
³Knight Cancer Institute, Immune Monitoring and Cancer Omics Services, Portland, OR

4816

Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Xindi Wang¹^*, Wenjing Luo¹^*, Zhaozhao Chen¹^*, Yu Hu^1,2^* and Heng Mei^1,2^*

¹Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
²Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China

4817

Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Kathrine S Rallis, MBBS, MSc¹, Jessica Liegel, MD², Giulia Cheloni, PhD³^*, Poorva Bindal, MD², Isabella Saldarriaga, BS³^*, Junyan Zhang²^*, Georges Chedid, MD²^*, Joseph Abirached, BS²^*, Jonah Lee, BS²^*, John G. Clohessy, PhD²^*, Samprity Ankita, BS²^*, Rajeev Relangi, BS²^*, Lina Bisharat, MS²^*, Hazal Toros, MS²^*, Sophia Adamia, PhD², Jasper B Lee, AB⁴^*, Donald Kufe, MD⁴^*, Kai W Wucherpfennig, MD, PhD⁴^*, Jacalyn Rosenblatt, MD³ and David Avigan, MD³

¹Beth Israel Deaconess Medical Center, Harvard Medical School, Brookline, MA
²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
³Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
⁴Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

4818

Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Abel Trujillo-Ocampo¹^*, Maison Grefe¹^*, Pamella Borges²^*, Jelita Clinton³^*, Hong He, MD, PhD⁴^*, Dan Li, PhD⁵^*, Ling Yu⁶^*, Martiela Vaz de Freitas⁷^*, Lisa St. John, PhD⁶^*, Karen Clise-Dwyer, PhD⁸^*, Gheath Alatrash, PhD, DO⁹, Dinler Amaral Antues¹⁰^*, Qing Ma, PhD¹¹^*, Jeffrey J. Molldrem, MD¹², Elizabeth J. Shpall, MD¹³ and Jin S. Im, MD, PhD¹³

¹The University of Texas MD Anderson Cancer Center, Department of Hematopoietic Biology and Malignancy, Houston, TX
²University of Houston, Department of Biology and Biochemistry, Houston
³The University of Texas MD Anderson Cancer Center, Department of Hematopoietic Biology and Malignancy, Houston
⁴Department of Hematopoietic Biology and Malignancy, University of Texas M.D. Anderson Cancer Center, Houston, TX
⁵University of Texas M.D. Anderson Cancer Center, Department of Hematopoietic Biology and Malignancy, Houston, TX
⁶Department of Hematopoietic Biology and Malignancy, University of Texas M. D. Anderson Cancer Center, Houston, TX
⁷the University of Houston, Department of Biology and Biochemistry, Houston, TX
⁸Department of Hematopoietic Biology & Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston
⁹Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Pearland, TX
¹⁰The University of Houston, Department of Biology and Biochemistry, Houston, TX
¹¹Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Departments of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

4819

Successful Generation of iPSC-Derived CD4⁺ and CD8⁺ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production

Dar Heinze, MD¹^*, Killian Sottoriva, PhD¹^*, Kristen Dettloff¹^*, Melissa Chin¹^*, Justin Gallagher¹^*, Alexa Galuppo¹^*, Kristen Fread, PhD¹^*, Justin Fang¹^*, Ryan Hasselkus²^*, Sarah Thomas¹^*, Eric Ma, PhD²^*, Ynes Helou, PhD¹^*, David Bauer, PhD¹^*, Jonathan Kurtz, PhD¹^*, Dustin Whitney, PhD¹^*, Chad Cowan, PhD²^* and G. Grant Welstead, PhD¹

¹Century Therapeutics, Boston, MA
²Clade Therapeutics, Boston, MA

4820

Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy

Arina Perez^*, Matthew S Hall, PhD^*, Sumei Lu, BSc^*, Brad Peterka, MSc^*, Michael Naso, Ph.D.^*, Hy Levitsky, MD and Buddha Gurung, Ph.D.^*

Century Therapeutics, Philadelphia, PA

4821

Universal Cloaking of Allogeneic T Cell Therapies Against Natural Killer Cells Via CD300a Agonism

G. Grant Welstead, PhD¹, Shuqi Zhang, PhD²^*, Justin Fang¹^*, Faith Thomas²^*, Andriana Lebid, Ph.D.³^*, Mike Miller, B.S.³^*, Daniel Perry, Ph.D.³^*, Dustin Whitney, PhD¹^*, Jill Carton³^*, Jonathan Kurtz, PhD¹^* and Chad Cowan, PhD²^*

¹Century Therapeutics, Boston, MA
²Clade Therapeutics, Boston, MA
³Century Therapeutics, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH